Evidence map›Paper›PMID 16082539›Full record

ArticleEuropean journal of clinical pharmacology2005

Initial treatment of hypertension and adherence to therapy in general practice in Italy.

Elisabetta Poluzzi, Petar Strahinja, Antonio Vargiu, Giacomo Chiabrando, Maria Chiara Silvani, Domenico Motola, Giulia Sangiorgi Cellini, Alberto Vaccheri, Fabrizio De Ponti, Nicola Montanaro

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical pharmacology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Trends in Prescription and Determinants of Persistence to Antihypertensive Therapy : The PAPEETE Study.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2009
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Choice of first antihypertensive--are existing guidelines ignored?British journal of clinical pharmacology · 2007
    Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Elisabetta PoluzziDepartment of Pharmacology, and Interuniversity Research Centre for Pharmacoepidemiology, University of Bologna, Via Irnerio 48, 40126 Bologna, Italy.
Petar Strahinja
Antonio Vargiu
Giacomo Chiabrando
Maria Chiara Silvani
Domenico Motola
Giulia Sangiorgi Cellini
Alberto Vaccheri
Fabrizio De Ponti
Nicola Montanaro

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAntihypertensive agents are among the most used therapeutic classes. The approach to the pharmacological treatment of hypertension is guided by international recommendations and adherence to treatment is known to result in effective prevention of cardiovascular risk.

aimThe aim of this study was to evaluate the pattern of use of antihypertensive agents in general practice in terms of drug choice for the initial treatment of hypertension and adherence to treatments among newly recruited patients.

methodsWe collected the data of all antihypertensive drugs prescribed by general practitioners (GPs) and reimbursed between January 1998 and December 2002 by a Local Health Authority of Emilia Romagna (Ravenna district, 350,000 inhabitants). We selected subjects aged 40 years and older, permanently living in the area during the whole period of the study, who received their first prescription of antihypertensives between January and December 1999, with no prescription of antihypertensive agents in the previous year. For each patient, we documented the starting regimen and evaluated adherence to treatment in terms of persistence during the years (patients were defined persistent if they received at least one prescription per year) and in terms of daily coverage (patients were defined covered if they received an amount of drugs consistent with a daily treatment). Finally, switches or addition of other therapeutic classes during the 3-year period were identified.

resultsA cohort of 6,043 subjects receiving their first antihypertensive treatment in 1999 was obtained. Regarding the starting regimen, monotherapies with angiotensin converting enzyme inhibitors (n = 1,597; 26%) or calcium channel blockers (n = 1126; 19%) were the most frequently prescribed. Of the patients, 21% started with a drug combination regimen. Regarding adherence to treatment, 18% of the cohort received only one prescription throughout the 3 years, 13% received more than one prescription but stopped the therapy during the first year, 69% were persistent during the second year and 60% also during the third year. Only 34% were covered during the first year and 24% also during the second year, whereas only 20% of the patients resulted covered throughout the 3 years. Among persistent patients, 41% maintained the same antihypertensive regimen throughout the 3 years, 25% added other drugs to the initial treatment and 34% switched to completely different regimens.

conclusionsOur findings reflect the lack of convergence among guidelines on the drug class(es) to be considered as first choice in the initial treatment of hypertension. Although an intervention in this field may have important implications in terms of cost savings, the ongoing debate does not allow us to draw definite conclusions on whether measures should be taken by the National Health Authority. However, the lack of adherence to antihypertensive treatment is undoubtedly a matter of concern for public health and should be addressed with appropriate interventions.

Indexed as

Patient CompliancePractice Patterns, Physicians'AdultAgedAged, 80 and overAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsCalcium Channel BlockersDrug UtilizationFamily PracticeFemaleHumansHypertensionItalyMaleMiddle AgedAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsCalcium Channel Blockers

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.